Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$2.13
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.13
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)1.13M
Market Cap
$81.47M
Enterprise Value$60.06M
Total Cash (Recent Filing)$16.54M
Total Debt (Recent Filing)$672.30K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding42,654,037
10 Day Avg. Volume2,003,928
30 Day Avg. Volume1,128,778
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.97
Forecast
1Y Price Target
$7.20Price Target Upside238.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone (IND Clearance)IND clearance for GT-02287 establishes a clear regulatory path to U.S. Phase 2, validating preclinical and early clinical work. This materially de-risks program progression, enables multi-region enrollment, and strengthens the company’s ability to attract partners and non-dilutive financing over the medium term.
Favorable Early Safety And Biomarker SignalsConsistent safety/tolerability and a robust biomarker reduction in the Phase 1b extension support target engagement and biological activity. Durable biomarker response and high retention across participants reduce early development risk and improve the chance Phase 2 can assess meaningful disease‑modifying endpoints.
Conservative Leverage ProfileExtremely low debt and minimal leverage lower bankruptcy and interest‑coverage risks, giving management structural flexibility in financing choices. A conservative capital structure helps preserve optionality for partnerships or equity financings during multi-year clinical development cycles.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicate material cash burn that must be financed externally. Persistent outflows constrain runway, raise dilution risk, and could force hurried financings that reduce strategic optionality during critical Phase 2 execution and readout periods.
Pre-revenue With Large LossesThe company remains pre-revenue with significant recurring losses, meaning no internal earnings to fund development. This structural profile requires ongoing capital raises to sustain operations and increases shareholder dilution risk while the company advances clinical programs over multiple years.
Limited Early Efficacy Evidence & Trial RiskEfficacy signals derive from small, open‑label cohorts and anecdotal reports, which limits confidence in translatability. Phase 2 will be the real test; execution, endpoint selection and multi‑site enrollment introduce binary clinical and operational risks that can materially affect long‑term value.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $81.47M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 29 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 42,654,037 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (238.03% Upside)
$7.20 (238.03% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.10%
12-Months-Change
Fundamentals
Return on Equity
-201.43%
Trailing 12-Months
Asset Growth
61.20%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(238.03% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
0.03%
Insiders
1.76% Mutual Funds
4.13% Other Institutional Investors
92.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---